These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 7805746

  • 21. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
    Samorski R, Gissmann L, Osen W.
    Immunol Lett; 2006 Sep 15; 107(1):41-9. PubMed ID: 16949679
    [Abstract] [Full Text] [Related]

  • 22. Tumor-associated E6 protein of human papillomavirus type 16 contains an unusual H-2Kb-restricted cytotoxic T cell epitope.
    Gao L, Walter J, Travers P, Stauss H, Chain BM.
    J Immunol; 1995 Dec 15; 155(12):5519-26. PubMed ID: 7499833
    [Abstract] [Full Text] [Related]

  • 23. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J.
    Gene Ther; 2000 Nov 15; 7(21):1859-66. PubMed ID: 11110419
    [Abstract] [Full Text] [Related]

  • 24. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
    Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S.
    Cancer Res; 1997 Nov 01; 57(21):4855-61. PubMed ID: 9354449
    [Abstract] [Full Text] [Related]

  • 25. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
    Giovane C, Trave G, Briones A, Lutz Y, Wasylyk B, Weiss E.
    J Mol Recognit; 1999 Nov 01; 12(2):141-52. PubMed ID: 10398405
    [Abstract] [Full Text] [Related]

  • 26. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
    Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH.
    Cancer Res; 2003 Feb 01; 63(3):636-41. PubMed ID: 12566307
    [Abstract] [Full Text] [Related]

  • 27. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
    Hu G, Liu W, Hanania EG, Fu S, Wang T, Deisseroth AB.
    Cancer Gene Ther; 1995 Mar 01; 2(1):19-32. PubMed ID: 7621252
    [Abstract] [Full Text] [Related]

  • 28. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
    Butz K, Whitaker N, Denk C, Ullmann A, Geisen C, Hoppe-Seyler F.
    Oncogene; 1999 Apr 08; 18(14):2381-6. PubMed ID: 10327059
    [Abstract] [Full Text] [Related]

  • 29. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
    Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM.
    Eur J Immunol; 1993 Sep 08; 23(9):2242-9. PubMed ID: 7690326
    [Abstract] [Full Text] [Related]

  • 30. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.
    Herd K, Fernando GJ, Dunn LA, Frazer IH, Lambert P, Tindle RW.
    Virology; 1997 Apr 28; 231(1):155-65. PubMed ID: 9143315
    [Abstract] [Full Text] [Related]

  • 31. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein.
    Nakagawa M, Kim KH, Gillam TM, Moscicki AB.
    J Virol; 2007 Feb 28; 81(3):1412-23. PubMed ID: 17108051
    [Abstract] [Full Text] [Related]

  • 32. Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7.
    Bauer S, Heeg K, Wagner H, Lipford GB.
    Scand J Immunol; 1995 Sep 28; 42(3):317-23. PubMed ID: 7660065
    [Abstract] [Full Text] [Related]

  • 33. Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis.
    Odunsi K, Ganesan T.
    Int J Mol Med; 2001 Oct 28; 8(4):405-12. PubMed ID: 11562779
    [Abstract] [Full Text] [Related]

  • 34. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein.
    Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F.
    Proc Natl Acad Sci U S A; 2000 Jun 06; 97(12):6693-7. PubMed ID: 10829072
    [Abstract] [Full Text] [Related]

  • 35. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins.
    Nakagawa M, Kim KH, Moscicki AB.
    Clin Diagn Lab Immunol; 2004 Sep 06; 11(5):889-96. PubMed ID: 15358648
    [Abstract] [Full Text] [Related]

  • 36. Generation and characterization of monoclonal antibodies against the E6 and E7 oncoproteins of HPV.
    Wlazlo AP, Giles-Davis W, Clements A, Struble G, Marmorstein R, Ertl HC.
    Hybridoma; 2001 Aug 06; 20(4):257-63. PubMed ID: 11604112
    [Abstract] [Full Text] [Related]

  • 37. Delayed-type hypersensitivity response to human papillomavirus type 16 E6 protein in a mouse model.
    Chambers MA, Stacey SN, Arrand JR, Stanley MA.
    J Gen Virol; 1994 Jan 06; 75 ( Pt 1)():165-9. PubMed ID: 7906707
    [Abstract] [Full Text] [Related]

  • 38. Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein.
    Kónya J, Eklund C, af Geijersstam V, Yuan F, Stuber G, Dillner J.
    J Gen Virol; 1997 Oct 06; 78 ( Pt 10)():2615-20. PubMed ID: 9349483
    [Abstract] [Full Text] [Related]

  • 39. The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP.
    Elston RC, Napthine S, Doorbar J.
    J Gen Virol; 1998 Feb 06; 79 ( Pt 2)():371-4. PubMed ID: 9472622
    [Abstract] [Full Text] [Related]

  • 40. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer.
    Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS.
    Nat Med; 1995 May 06; 1(5):464-70. PubMed ID: 7585096
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.